Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

Robert T O'Donnell, Yunpeng Ma, Hayes C. McKnight, David Pearson, Joseph Tuscano

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts'. Together they form a unique fingerprint.

Medicine & Life Sciences